Variable | Median (Range) | |
---|---|---|
Time between 1st and 2nd radiotherapy | 17 months (4–176 months) | |
Initial radiation dose, EQD2 (α/β = 10) | 68.0 Gy (30.8 Gy – 72.0 Gy) | |
Re-irradiation dose, EQD2 (α/β = 10) | 58.4 Gy (3.7 Gy – 66.0 Gy) | |
Re-irradiation dose for RT completion group, EQD2 (α/β = 10) | 58.4 Gy (30.1 Gy – 66.0 Gy) | |
Re-irradiation dose for the RT non-completion group, EQD2 (α/β = 10) | 27.45 Gy (3.7 Gy – 47.8 Gy) | |
Intended re-irradiation dose for the non-completion group, EQD2 (α/β = 10) | 58.4 Gy (49.6 Gy − 66.0 Gy) | |
Cumulative radiation dose, EQD2 (α/β = 10) | 122.8 Gy (63.7 Gy – 132.0 Gy) | |
Cumulative radiation dose for the boost-group, EQD2 (α/β = 10) | 124.0 Gy (89.2 Gy – 132.0 Gy) | |
Cumulative radiation dose for the no boost-group, EQD2 (α/β = 10) | 119.1 Gy (63.7 Gy – 131.6 Gy) | |
PTV | 105.1 cm3 (16.7 cm3–905.3 cm3) | |
Cumulative Dmaxspinal cord, EQD2 (α/β = 3) | 41.0 Gy (9.9 Gy – 74.8 Gy) | |
 | n | % |
Radiotherapy | ||
 definitive | 31 | 64.6 |
 adjuvant | 17 | 35.4 |
Completion radiotherapy | ||
 no | 6 | 12.5 |
 yes | 42 | 87.5 |
Boost | ||
 no boost | 33 | 68.8 |
 integrated boost | 10 | 20.8 |
 sequential boost | 5 | 10.4 |
Simultaneous chemotherapy | ||
 no | 20 | 41.7 |
 yes | 28 | 58.3 |
Chemotherapy,n = 28 | ||
 cetuximab | 17 | 60.7 |
 cisplatin | 8 | 28.6 |
 cisplatin/5-fluorouracil | 1 | 3.6 |
 cisplatin/cetuximab | 1 | 3.6 |
 carboplatin | 1 | 3.6 |